6.11.2017
EN
Official Journal of the European Union
C 374/27
Judgment of the General Court of 21 September 2017 — Novartis v EUIPO — Meda (Zimara)
(Case T-238/15) (1)
((EU trade mark - Opposition proceedings - Application for the EU word mark Zimara - Earlier EU word mark FEMARA - Relative ground for refusal - Article 8(1)(b) of Regulation (EC) No 207/2009 - Article 75 of Regulation No 207/2009 - Article 76(1) of Regulation No 207/2009 - Obligation to decide on the entirety of the appeal - First sentence of Article 64(1) of Regulation No 207/2009))
(2017/C 374/40)
Language of the case: English
Parties
Applicant: Novartis AG (Basle, Switzerland) (represented by M. Douglas, lawyer)
Defendant: European Union Intellectual Property Office (represented by H. O’Neill, acting as Agent)
Other party to the proceedings before the Board of Appeal of EUIPO: Meda AB (Solna, Sweden)
Re:
Action brought against the decision of the Fifth Board of Appeal of EUIPO of 6 March 2015 (Case R 636/2014-5) relating to opposition proceedings between Novartis and Meda.
Operative part of the judgment
The Court:
1.
Annuls the Decision of the Fifth Board of Appeal of the European Union Intellectual Property Office (EUIPO) of 6 March 2015 (Case R 636/2014-5) in so far as the Board of Appeal failed to rule on the appeal before it as regards ‘veterinary preparations’;
2.
Dismisses the remainder of the action;
3.
Orders each party to bear its own costs.
(1) OJ C 228, 13.7.2015.
Full & Egal Universal Law Academy